Biomaterial-Assisted CRISPR-Cas9 Editing of T Cells: From Editing Percentage to Functional Cell Yield

Biomaterial-assisted delivery may improve CRISPR-Cas9 engineering of therapeutic T cells, but the processperformance cannot be measured by the editing percentage alone. This critical narrative review investigates selected evidence from primary human T-cell editing ex vivo and takes into account the murine in vivo studies separately. We compared the four approaches, lipid nanoparticles (LNPs), peptide-mediated delivery, polymer-assisted workflows, and localized physical-delivery systems, which differ in cargo requirements, intracellular barriers, and the strength of evidence for their effects on T-cell function. Although the outcomes are proposed to be related, they need to be assessed separately since allele-level editing, loss of surface protein expression, reporter positivity, targeted insertion, viable-cell recovery, and therapeutic function measure different aspects of the process. More viable edited cells may be recovered in absolute terms even when the percentage of cells edited is lower. Nor does a successful insertion, by itself, show that receptor expression from the genome will last or that the cells will have potency. Recovering more cells is not enough if there is still uncertainty either about the intended genotype or genomic integrity. In this article, we propose a framework for the minimum information to report. Edit identity, viable edited-cell output, functional qualification, genome safety, and manufacturing efficiency are considered separately. The studies show that particular experimental workflows can be improved, yet they fail to provide enough evidence to rank the delivery methods. Future studies should establish how many functional, successfully edited cells are obtained under consistent experimental conditions that are clearly documented, and relate this output to delivery performance.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-16
DOI
https://doi.org/10.5281/zenodo.24277307
Primary Topic
CRISPR and Genetic Engineering
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Biomaterial-Assisted CRISPR-Cas9 Editing of T Cells: From Editing Percentage to Functional Cell Yield

Seungbin Kim, Seungyeon Kim
2 links
Zenodo (CERN European Organization for Nuclear Research)
CRISPR and Genetic Engineering
preprint

Biomaterial-Assisted CRISPR-Cas9 Editing of T Cells: From Editing Percentage to Functional Cell Yield

Seungbin Kim, Seungyeon Kim
preprint en

Abstract

Biomaterial-assisted delivery may improve CRISPR-Cas9 engineering of therapeutic T cells, but the processperformance cannot be measured by the editing percentage alone. This critical narrative review investigates selected evidence from primary human T-cell editing ex vivo and takes into account the murine in vivo studies separately. We compared the four approaches, lipid nanoparticles (LNPs), peptide-mediated delivery, polymer-assisted workflows, and localized physical-delivery systems, which differ in cargo requirements, intracellular barriers, and the strength of evidence for their effects on T-cell function. Although the outcomes are proposed to be related, they need to be assessed separately since allele-level editing, loss of surface protein expression, reporter positivity, targeted insertion, viable-cell recovery, and therapeutic function measure different aspects of the process. More viable edited cells may be recovered in absolute terms even when the percentage of cells edited is lower. Nor does a successful insertion, by itself, show that receptor expression from the genome will last or that the cells will have potency. Recovering more cells is not enough if there is still uncertainty either about the intended genotype or genomic integrity. In this article, we propose a framework for the minimum information to report. Edit identity, viable edited-cell output, functional qualification, genome safety, and manufacturing efficiency are considered separately. The studies show that particular experimental workflows can be improved, yet they fail to provide enough evidence to rank the delivery methods. Future studies should establish how many functional, successfully edited cells are obtained under consistent experimental conditions that are clearly documented, and relate this output to delivery performance.

Zenodo (CERN European Organization for Nuclear Research)
Ghent University Global Campus (KR)
Good health and well-being
CRISPR and Genetic Engineering
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon